


| Revenue | $100 - $500 million See Exact Annual Revenue |
|---|---|
| Employees | 100 - 500Exact Company Size |
| Primary Industry | 325411 Medicinal & Botanical Manufacturing |
| Additional NAICS Codes | 325412 Pharmaceutical Preparation Manufacturing |
| Address | 400 Knightsbridge Pkwy Lincholnshire, IL 60069 |
| Nexus Pharmaceuticals | Revenue Est. ($ Million) | Growth Rate (%) | # Employees |
|---|---|---|---|
| 2025 | $100 - $500 million Details in Premium Report | ||
| 2024 | |||
| 2023 | |||
| 2021 | |||
| 2020 | |||
| 2019 | |||
|
1-Year Growth Rate: 3-Year Growth Rate (CAGR): | ![]() |
| Nexus Pharmaceuticals P&L | $ Millions |
|---|---|
| Revenue (Sales) | ![]() |
| Cost of Goods Sold | |
| Gross Profit | |
Operating Expenses | |
| Advertising | |
| Salaries and wages | |
| Other Operating Expenses | |
| Total Operating Expenses | |
| Operating Income | |
| EBITDA | |
| EBIT (Earnings Before Interest and Taxes) | |
| Net Profit | |
| Trademark | Date |
|---|---|
| CONNECTING MOLECULES TO MEDICINE Pharmaceutical preparations for the treatment of ocular disorders; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of metabolic disorders; Pharmaceutical preparations for the treatment of endocrine disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of blood pressure disorders; Pharmaceutical preparations for the treatment of blood clotting disorders; Pharmaceutical preparations for the treatment of cancer-related conditions; Pharmaceutical preparations for the treatment of psychotic diagnoses; Pharmaceutical preparations for the treatment of gastrointestinal conditions | 09/22/2020 |
| EMERPHED Pharmaceutical preparations for the treatment of hypotension | 04/21/2020 |
| N NEXUS PHARMACEUTICALS, INC. Ophthalmic preparations; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical products for ophthalmological use | 08/26/2015 |
| Company | Headquarters | Revenue ($ MM) |
|---|---|---|
| XYMOGEN | Orlando, FL | 100 |
| AVANTI NUTRITIONAL LABORATORIES | Miami Lakes, FL | 37 |
| NUTRITION FORMULATORS | Miramar, FL | 36 |
| RTPR | Cabot, AR | 33 |
| INTEGRATED BOTANICS | Fort Worth, TX | 29 |
| COSMAX NBT USA | Garland, TX | 29 |
| CJB INDUSTRIES | Valdosta, GA | 28 |
| ALTERNATIVE LABORATORIES | Naples, FL | 28 |
| S&B PHARMA | Azusa, CA | 28 |
| Company | Headquarters | Revenue ($ MM) |
|---|---|---|
| ABBOTT LABORATORIES | Abbott Park, IL | 100 |
| ALLERGAN | North Chicago, IL | 67 |
| ASTELLAS US | Northbrook, IL | 11 |
| FRESENIUS KABI | Lake Zurich, IL | 11 |
| HOSPIRA | Lake Forest, IL | 10 |
| HORIZON THERAPEUTICS USA | Deerfield, IL | 5 |
| Company | Revenue ($ MM) |
|---|---|
![]() | |